BCL7A
Overview
BCL7A is a SWI/SNF-associated gene recurrently mutated in B-cell lymphomas, where AID-mediated off-target mutagenesis generates non-coding and coding lesions.
Alterations observed in the corpus
- Mutated in 18% of classic Hodgkin lymphoma cases in the 61-patient WGS+WES cohort PMID:36723991.
- Showed an elevated noncoding-to-coding mutation ratio consistent with AID off-target activity, along with SOCS1, TMSB4X, IL4R, and ITPKB PMID:36723991.
- Timed as an early event in cHL pathogenesis, preceding whole-genome duplication and large chromosomal gains PMID:36723991.
- Recurrent translocation involving BCL7A detected by low-pass WGS in 5/106 endometrial carcinoma tumors (ucec_tcga_pub); predicted in-frame fusions with increased BCL-family expression PMID:23636398
- Implicated in one or two PCNSL cases as part of focal amplification or homozygous deletion events in genome-wide analysis of 18 PCNSL samples PMID:25991819
Cancer types (linked)
- Classic Hodgkin lymphoma — BCL7A is among the eight driver genes newly described in cHL by the WGS HRS-cell study PMID:36723991.
Co-occurrence and mutual exclusivity
- Co-occurs in the early-event window with B2M, GNA13, and PTPN1 in cHL PMID:36723991.
Therapeutic relevance
- No direct BCL7A-targeted therapy is reported in the corpus PMID:36723991.
Open questions
- Functional consequences of BCL7A mutation in HRS cells, and whether the noncoding AID footprint changes expression, are not resolved PMID:36723991.
Sources
This page was processed by crosslinker on 2026-05-14. - PMID:23636398
This page was processed by crosslinker on 2026-05-14. - PMID:25991819
This page was processed by crosslinker on 2026-05-14.